HuidaGene Therapeutics receives FDA Rare Pediatric Disease Designation for inherited blindness treatment

The U.S. Food and Drug Administration (FDA) had granted Rare Pediatric Disease Designation (RPDD) to HuidaGene Therapeutics’ HG004 for the treatment of inherited retinal disease caused by RPE65 mutations(RPE65-IRDs).

The FDA grants RPDD to incentivise development of new treatments for serious or life-threatening diseases that primarily affect children ages 18 years or younger with fewer than 200,000 people affected in the U.S.

The RPDD program allows for a sponsor who receives an approval to qualify for a priority review voucher (PRV) that can be deemed to receive an expedited six-month priority review for any subsequent marketing application or may be sold or transferred.

PRVs have historically commanded prices in excess of $100 million USD with the highest price paid for a PRV $350 million USD. For a large company launching a billion-dollar drug, the six-month acceleration in regulatory review can be of substantial economic value. Most recently, Sarepta Therapeutics sold a PRV for $102 million USD.

“This Rare Pediatric Disease designation from the US FDA highlights the significant unmet medical need that HuidaGene is seeking to address with HG004 for RPE65-IRDs,” said Alvin Luk, Ph.D., M.B.A., C.C.R.A., co-founder and Chief Executive Officer of HuidaGene.

“HG004 was granted both RPDD and orphan drug designation (ODD) by the US FDA in March, allowing tax credits for clinical development, exemptions for certain FDA application fees, 7-year of market exclusivity, and assistance in the drug development process. We look forward to advancing HG004 in the clinic and remain steadfast in our commitment to answering patients worldwide.”

“We are pleased to have received another significant regulatory feedback from the US FDA underscoring the dire need for a treatment option of this devastating inherited blindness,” said Linyu Shi, Ph.D., co-founder and chief scientific officer of HuidaGene.

“Data from our preclinical studies have shown that HG004 demonstrates significant superiority than AAV2-hRPE65 (LUXTURNA like) in the recovery of retinal function of the Rpe65-/- mice. We are committed to delivering transformative genetic medicines for rare genetic diseases globally.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news